Mirabet – First β3 for Over Active Bladder launched in Afghanistan

  • Home
  • News Feeds
  • Mirabet – First β3 for Over Active Bladder launched in Afghanistan

KABUL, APRIL 2019: With the commitment of enabling healthy and happy lives by providing quality healthcare products globally, CCL’s International Operations function has recently introduced Mirabet, the first ever Mirabegron in Afghanistan.

The launch symposium was organized in Singapore and was attended by 18 leading Afghan doctors. CCL’s IntOps engaged Dr. Abdul Saboor, Chief Medical Specialist as a speaker for conducting the clinical session of Mirabet. He highlighted the growing prevalence of over active bladder in Afghan population and limited treatment options.

He briefed the participants regarding selectivity and clinical advantages of Mirabegron (Mirabet) over other available treatment options. The event was moderated by Saleem Shah, CCL’s Country Manager for Afghanistan and Sajid Shah, Sales Manager, Afghanistan.

Further launch symposia are also being organized in Afghanistan by sales managers engaging top urologists, gynecologists and physicians.

web-ccl


Leave a Reply

Your email address will not be published. Required fields are marked *